3CL Protease Inhibitor NLC-001 Added to COVID-19-focused Joint Venture Between Todos Medical and NLC Pharma

  •  NLC-001 is a proprietary blend of plant extracts administered orally as dietary supplement
  •  US FDA granted Certificate of Free Sale for NLC-001 on August 28, 2020
  •  JV evaluating potential of NLC-001 to treat COVID-19 in clinical studies in Israel
  •  Todos evaluating commercialization options for NLC-001 Worldwide

NEW YORK, REHOVOT, Israel and SINGAPORE, Sept. 17, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on developing and distributing comprehensive solutions for COVID-19, and developing blood tests for the early detection of cancer and Alzheimer’s disease, today announced that NLC Pharma has added the dietary supplement NLC-001 to its joint venture with Todos Medical. NLC-001 is an orally administered proprietary blend of plant extracts that includes a powerful potential 3CL protease inhibitor that could help support and maintain healthy immune function. The 3CL protease plays a vital role in the intracellular replication

Read More

Element Science Names Zubin J. Eapen, MD as Chief Medical Officer

Experienced Cardiologist Brings Expertise in Launching and Scaling Innovative Models of Care

Element Science, an innovative health technology company pioneering a next-generation digital wearable platform for high-risk cardiovascular patients transitioning from hospital to home, announced today that it has appointed Zubin J. Eapen, MD, MHS, FACC, FAHA, as Chief Medical Officer. Dr. Eapen, an experienced health system leader who has launched and scaled innovative models of care and overseen numerous clinical trials, will help advance the Company’s initial product, the Jewel Patch Wearable Cardioverter Defibrillator (P-WCD).

The Jewel P-WCD is the first product built on the novel Jewel platform, which is designed to help patients reduce their need for hospitalization through diagnostic, therapeutic, and connected capabilities. The Jewel platform is an unobtrusive, low-profile personal defibrillator designed to detect and treat life-threatening arrhythmias in patients with an elevated temporary risk of Sudden Cardiac Death (SCD), a condition more than 500,000 patients

Read More

New Education Policy will suffocate medical education

The National Working Committee formed under the Indian Medical Association (IMA) has raised serious concerns about the National Education Policy 2020, especially with reference to medical education. It has submitted a detailed write up of point-by-point lapses in the new policy, stating that if it is accepted in its present form, it will suffocate medical education.

The union government introduced the National Education Policy 2020, seeking public opinion, saying it is the first education policy of the 21st century and aims to address the many growing developmental imperatives of our country. This policy proposes the revision and revamping of all aspects of the education structure, including its regulation and governance, to create a new system that is aligned with the aspirational goals of 21st century education.

The NEP states that all students of allopathic medical education must have a basic understanding of Ayurveda, Yoga and Naturopathy, Unani, Siddha, and Homeopathy (AYUSH), and vice versa. PIC/gettyimagesThe NEP states that all students of allopathic medical education must have a basic understanding of Ayurveda, Yoga and Naturopathy, Unani, Siddha, and Homeopathy

Read More

Orthopaedic Research UK and Embryo Ventures Launch Novara Therapeutics to Accelerate Commercialisation of Pioneering Medical Technology

Joint Venture Company Novara Therapeutics is set to advance diagnosis and treatment of bone fractures through a patented bone-targeting contrast agent.

Orthopaedic Research UK (ORUK) and Embryo Ventures (Embryo) announce the formation of Novara Therapeutics, a joint venture company, to commercialise a patented bone-targeting contrast agent. Novara Therapeutics will focus on pre-clinical development of the proprietary imaging and therapeutic technology to advance diagnosis and treatment of bone disease in patients.

Osteoporosis is the most common bone disease, affecting over 200 million people worldwide1. The condition is characterised by a progressive reduction in bone mass and strength that results in more than 8.9 million osteoporotic fracture annually1. With one in three women and one in five men aged over 50 years experiencing an osteoporotic fracture in their lifetime, the condition poses a major public health challenge that is expected to increase markedly as the world’s ageing population

Read More

Big Questions on Medical and Bio-Engineering

The online forum features a speaker lineup of world-renowned scholars who will discuss an array of bio-engineering technologies that will improve our quality of life and even extend our life span. This is the GSI’s third online forum since the first one in April that covered the socio-economic implications of the global pandemic and the second one in June focusing on the education sector.

In hosting the third round of the GSI Forum series, KAIST President Sung-Chul Shin stressed the power of science and technology saying, “In this world full of uncertainties, one thing for sure is that only the advancement of science and technology will deliver us from this crisis.” Korean Prime Minister Sye-Kyun Chung will also deliver a speech explaining the government’s response to COVID-19 and vaccine development strategies.

The President of the National Academy of Medicine in the US will share ideal policies to back up the

Read More

Reforming medical education requires redefining the physician’s role

Much like the COVID-19 pandemic has shed light on long-time cracks in the
 U.S. healthcare system, it also highlights gaps in medical education. What needs to change for the future of medical education? Enhancing physician training to bolster improvements to Americans’ health first requires an institutional shift in defining 
the physician’s role.

Though U.S. healthcare and medical education have advanced in the last century, both still fall short of the goal to protect and promote the health of every American. Even before a global pandemic, Americans have long been plagued by public health crises including socio-economic challenges, structural racism, widespread inequity, and a recent decline in life expectancy.

Consequently, a multitude of recommendations to improve the medical education of future providers is complicated by increasing demands on medical students. Perhaps the fundamental question to guide solutions for training future generations of physicians is: What role is a medical student taught

Read More

Artio Medical Appoints Paul Muller as Chief Technology Officer and General Manager

“Paul is a highly skilled engineer and seasoned industry veteran with exceptional team-building and leadership skills who has demonstrated a successful track record developing novel, market-leading medical devices,” stated Dr. F. Nicholas Franano, President and CEO of Artio Medical. “We are thrilled to have someone with Paul’s talent and vision leading product development at Artio.”

Previously, Mr. Muller was CTO and GM at Flow Forward Medical (recently acquired by Artio) where he managed the development of Flow Forward’s Arteriovenous Fistula Eligibility (AFE) System™, a small, temporary, external blood pump system for kidney failure patients that stimulates vein enlargement prior to the creation of vascular access sites for hemodialysis. Paul previously held leadership positions and achieved major engineering and product development milestones at Thoratec (subsequently acquired by St. Jude Medical and Abbott) and Guidant (subsequently acquired by Abbott). Mr. Muller is a named inventor on 31 patents, and he has

Read More

Therma Bright Acquires Benepod(R) Pain Relief Technology and Other Innovative Medical Device Technology from Saringer Life Science Technologies Inc.

® pain relief technology and other innovative medical device technology from Saringer Life Science Technologies Inc. (“Saringer” or “SLST Inc.”). After completion of final negotiations, Therma acquired the Saringer assets in an all cash transaction for $425,000.” data-reactid=”19″Toronto, Ontario–(Newsfile Corp. – August 26, 2020) – Therma Bright Inc. (TSXV: THRM), (“Therma Bright” or the “Company”), a progressive medical device technology company, is pleased to announce that it has closed the transaction to acquire Benepod® pain relief technology and other innovative medical device technology from Saringer Life Science Technologies Inc. (“Saringer” or “SLST Inc.”). After completion of final negotiations, Therma acquired the Saringer assets in an all cash transaction for $425,000.

Read More